Analysis of the tumor-bearing lungs at day 26 revealed that the combination of IV BCG with ICB further enhanced the functionality of lung CD8+ T cells, including the tumor-specific (gp33-dextramer-positive), when compared to BCG alone (Fig. 9f). This evidence concerns the gene CD8A and neoplasm.